Market research
0IT.F iCo Therapeutics Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 2.73
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 2.73
About
About iCo Therapeutics Inc
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program focuses on the development of a therapeutic for correcting the impaired muscle regenerative process in Duchenne muscular dystrophy (DMD), a genetic disease that involves the mutation and functional disruption of the DMD gene and loss of Dystrophin. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Research context
iCo Therapeutics Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 0IT.F discussion.
5 years, 6 months ago
iCo Therapeutics Inc is currently in a long term uptrend where the price is trading 72.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
iCo Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 62.5% to $-193K since the same quarter in the previous year.
Finally, its free cash flow grew by 70.9% to $-193K since the same quarter in the previous year.
Based on the above factors, iCo Therapeutics Inc gets an overall score of 4/5.